Main Menu
Untitled Page
Home > Equity > Company info > Company Snapshot
05 June 2020

Search Quotes

  Enter at least 3 characters from BSE Code for a company or the company's name

Cipla Ltd (Pharmaceuticals - Indian - Bulk Drugs & Formln)

Last Price 660.55
Net Changes 19.35
Volume 10452588
Prev Close 641.20
660.55 19.35 (3.02%)
Date: Jun 04,2020 EOD




Index Details Pharmaceuticals - Indian - Bulk Drugs & Formln


Chart

Stock Price Details

Market Statistics

Open Price 644 Div Yield (%) 0.61
Buy (Size) 660.90(×717) Eps(Rs) 28.75
Sell (Size) 660.90(×81) Book Value (Stand.)(Rs) 215.85
Value 20746799600 Book Value(conso.)(Rs) 195.5050371
Buy Quantity 717 Market Cap(Rs.Cr) 53286.45
Sell Quantity 81 Face Value(Rs) 2
Today's High 665 Market Lot 1
Today's Low 644 AGM Date Aug
52-Week High 665 Book Closure Date Aug
52-Week Low 356.75 ISIN No. INE059A01026

Share Holding Pattern

  No Of shares % Share Holding
Total Foreign (Promoter & Group) 174907187 21.69
Indian (Promoter & Group) 120578409 14.96
Total of Promoter 295485596 36.65
Non Promoter (Institution) 327190760 40.58
Non Promoter (Non-Institution) 182964941 22.69
Total Non Promoter 510155701 63.28
Total Promoter & Non Promoter 805641297 99.93
Custodians(Against Depository Receipts) 594032 0.07
Grand Total 806235329 100.00

Company News

02-Jun-2020  Cipla Ltd - Cipla Limited - Allotment of ESOP/ESPS
Cipla Ltd - Cipla Limited - Allotment of ESOP/ESPS

Cipla Limited has informed the Exchange regarding allotment of 31762 Equity Shares under ESOP
01-Jun-2020  Cipla Ltd - Cipla Limited - Disclosure under SEBI Takeover Reg...
Cipla Ltd - Cipla Limited - Disclosure under SEBI Takeover Regulations

Cipla Limited has informed the Exchange regarding disclosure Regulation 30(1), 30(2) and 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011
28-May-2020  Cipla Ltd - Cipla Limited - Analysts/Institutional Investor Me...
Cipla Ltd - Cipla Limited - Analysts/Institutional Investor Meet/Con. Call Updates

Cipla Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates
27-May-2020  Cipla Ltd - Announcement under Regulation 30 (LODR)-Analyst /...
Cipla Ltd - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed is the schedule of Analyst / Institutional Investor Meetings with the Company.
22-May-2020  Cipla Ltd - Announcement under Regulation 30 (LODR)-Analyst /...
Cipla Ltd - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Please find enclosed schedule of Analyst / Institutional Investor Meetings of the Company.
21-May-2020  Cipla receives USFDA final approval for Dihydroergotamine Mesy...
Cipla receives USFDA final approval for Dihydroergotamine Mesylate Nasal Spray

Cipla has received final approval for its Abbreviated New Drug Application (ANDA) for Dihydroergotamine Mesylate Nasal Spray 4mg/mL from the United States Food and Drug Administration (U.S. FDA) with a Competitive Generic Therapy (CGT) designation.

Cipla is the “first approved applicant” for such CGT and, is therefore, eligible for 180 days of CGT exclusivity which will begin to run from the commercial marketing of Cipla's product. This 180-day CGT exclusivity will not block the commercialization of the existing approvals of Dihydroergotamine Mesylate Nasal Spray, 4 mg/mL.

Cipla's Dihydroergotamine Mesylate Nasal Spray 4mg/mL is AB-rated generic therapeutic equivalent version of Bausch Health US LLC's Migranal®. This is Cipla's first ANDA approval for a nasal spray. It is indicated for the acute treatment of migraine headaches with or without aura.

According to IQVIA (IMS Health), Migranal® and its authorized generic equivalents had U.S. sales of approximately $102M for the 12-month period ending March 2020.

Cipla's product is available for shipping immediately.

21-May-2020  Cipla gets final USFDA nod for migraine-treatment nasal spray
Cipla gets final USFDA nod for migraine-treatment nasal spray

Cipla is the first approved applicant for such CGT and, is therefore, eligible for 180 days of CGT exclusivity which will begin to run from the commercial marketing of Cipla's product. However, the CGT designation will not block the commercialization of the existing approvals of the said product.

The Dihydroergotamine Mesylate nasal spray is AB-rated generic therapeutic equivalent version of Bausch Health US' Migranal. This is Cipla's first ANDA approval for a nasal spray. It is indicated for the acute treatment of migraine headaches with or without aura.

According to IQVIA (IMS Health), Migranal and its authorized generic equivalents had US sales of approximately $102 million for the 12-month period ending March 2020.

Cipla is a global pharmaceutical company focused on complex generics, and deepening portfolio in India, South Africa, North America, and key regulated and emerging markets.

On a consolidated basis, the drug maker's net profit declined 33% to Rs 245.95 crore on a 0.7% rise in net sales to Rs 4301.60 crore in Q4 March 2020 over Q4 March 2019.

Shares of Cipla was currently down 0.45% at Rs 617.55. It has traded in the range of Rs 613.15 and Rs 626.60 so far during the day.

21-May-2020  Cipla Ltd - Announcement under Regulation 30 (LODR)-Press Rele...
Cipla Ltd - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Cipla Limited receives final approval for generic version of Migranalr (Dihydroergotamine Mesylate Nasal Spray 4mg/mL) with a Competitive Generic Therapy Designation
19-May-2020  Cipla Ltd - Announcement under Regulation 30 (LODR)-Analyst /...
Cipla Ltd - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Pursuant to regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed schedule of Analyst / Institutional Investor Meetings with the Company.
19-May-2020  Cipla Ltd - Announcement under Regulation 30 (LODR)-Earnings C...
Cipla Ltd - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

Please find enclosed copy of the transcript of the Companys Q4 FY20 earnings conference call dated 15th May, 2020. The transcript is also available on the Companys website i.e. www.cipla.com under the Investors section.
Incorporation Year 1935 
Registered Office Cipla House Peninsula Buss Par,Ganpatrao Kadam Mg Lower Parel,
Mumbai,
Maharashtra-400013
Telephone 91-22-24826000 
Fax 91-22-24826120 
Chairman Y K Hamied
Managing Director Umang Vohra
Company Secretary Rajendra Chopra 
Auditor Walker Chandiok & Co LLP 
Face Value(Rs)
Market Lot
Listing BSE,Luxembourg,MSEI,NSE 
Registrar KFin Techologies Pvt Ltd
Karvy Selenium Tow-B,31&32 Financial Dist,Nanakramguda,Hyderabad-500032 
Toll Free number: 1800-425-5501 / 1800-103-5501
FINANCIAL TOOLS